Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
HAMPTON, N.J., March 03, 2016 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, will provide a corporate overview at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8, 2016 at 10:00 a.m. EST in Boston.
The live webcast of the presentation will be available on the “Events & Presentations” page of the “Investors & Media” section of the Celldex website. A replay of the presentation will be archived for seven days following the event.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
Contact: Sarah Cavanaugh Vice President of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 [email protected] Charles Liles Manager of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3107 [email protected]
